医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MetLife’s New Blockchain Health Insurance Product Eliminates Claims

2018年08月21日 AM10:24
このエントリーをはてなブックマークに追加


 

SINGAPORE

MetLife Asia’s Singapore-based innovation center, LumenLab, has begun testing the world’s first, automated insurance solution using blockchain technology to offer pregnant women financial protection in case of gestational diabetes, without ever needing to make a claim.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005644/en/

The experimental product, known as “Vitana,” is Singapore’s first dedicated insurance product for gestational diabetes – a condition affecting up to one in five expectant mothers in Singapore.[i] Vitana securely connects to customers’ electronic medical records via their mobile device to issue a policy within minutes. It triggers an automatic payout upon diagnosis, without the need to make a claim.

“Vitana embodies MetLife’s commitment to its customers. In today’s world, people expect experiences to be simple, automated, and digital. We saw an opportunity to test how blockchain can make insurance more seamless and we’ve partnered with some of the best companies in their fields to create a blueprint to launch new parametric insurance products in the future,” said Zia Zaman, MetLife’s Chief Innovation Officer in Asia and Chief Executive Officer of LumenLab.

In addition to an enhanced experience, Vitana offers customers improved data security as it performs parametric underwriting on the customer’s mobile device, meaning the insurance company doesn’t require access to the underlying medical data to confirm insurability.

Vitana was built with partners: SwissRe, which helped drive product design and reinsure the risk; Cognizant, which provided the underlying technology and blockchain expertise; and Vault Dragon, an electronic medical records provider which supported on-the-ground implementation with forward-thinking doctors and clinics. Vitana was developed within the Monetary Authority of Singapore’s (MAS) regulatory sandbox, and was highlighted in MAS’ annual report as one of the key innovations to come out of the sandbox initiative.

“Experimentation is crucial to invent and create the future. We are glad that the sandbox has enabled LumenLab to jumpstart an innovative experiment within safe boundaries, to understand if it could effectively address existing pain points of both the insured and insurer, before rolling it out on a broader scale,” said Sopnendu Mohanty, Chief FinTech Officer, MAS.

Customers can download Vitana via the App Store to receive up to SGD 2,500 coverage for medical expenses associated with gestational diabetes. The experiment will run over a six-month period and LumenLab is working with the Singapore Medical Group Women’s Health as well as other select clinics to offer the solution to Singapore-based patients in their first 23 weeks of pregnancy (see FAQs for a full list of clinics).

To learn more about Vitana, visit http://www.vitana.sg/ or read the FAQs.

About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help its individual and institutional customers navigate their changing world. Founded in 1868, MetLife has operations in more than 40 countries and holds leading market positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com

About LumenLab
As MetLife’s pioneer for disruptive innovation, LumenLab is charging ahead to create new businesses in health, wealth and retirement. Lumen, a measure of light, symbolizes our commitment to illuminating a new path for solving the problems that the people of Asia face today. Through our focus on building new products and services grounded in technology and data, we aim to help people achieve richer and more fulfilling lives. For more information, visit www.lumenlab.sg

i Gusto, a longitudinal baby study at NUH and the KK Women’s and Children’s Hospital (KKH) (Khalik, S. 2016).

View source version on businesswire.com: https://www.businesswire.com/news/home/20180820005644/en/

CONTACT

MetLife Asia
Yvette Marmur, +852 5716 8533
ymarmur@metlife.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Alvotech与富士制药缔结排他性伙伴关系,在日本从事生物类似物的开发和商业化
  • アルヴォテックと富士製薬が日本でバイオシミラーを開発・商業化するための独占提携契約を締結
  • Dynex Technologies获得CFDA核准,向中国供应AGILITY自动ELISA处理系统
  • Alvotech and Fuji Pharma Enter into Exclusive Partnership for Development and Commercialization of Biosimilars in Japan
  • SANYEI CORPORATION Based in Japan Launches ION-Sei™ into the UK Market in Time for the Christmas Season. A Unique Electric Toothbrush That Uses Patented Technology to Suppress Bacteria That Cause Plaque and Gum Disease